Emerging role of a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist in bronchial asthma in vivo: antioxidant activity and the down-regulation of inflammatory factors
El-Naa, M., El-Refaei, M., Nasif, W., El-Brairy, A. (2014). Emerging role of a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist in bronchial asthma in vivo: antioxidant activity and the down-regulation of inflammatory factors. EKB Journal Management System, 10(1), 1-13. doi: 10.21608/blj.2014.63402
Mona M. El-Naa; Mohamed F. El-Refaei; Wesam A. Nasif; Amany I. El-Brairy. "Emerging role of a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist in bronchial asthma in vivo: antioxidant activity and the down-regulation of inflammatory factors". EKB Journal Management System, 10, 1, 2014, 1-13. doi: 10.21608/blj.2014.63402
El-Naa, M., El-Refaei, M., Nasif, W., El-Brairy, A. (2014). 'Emerging role of a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist in bronchial asthma in vivo: antioxidant activity and the down-regulation of inflammatory factors', EKB Journal Management System, 10(1), pp. 1-13. doi: 10.21608/blj.2014.63402
El-Naa, M., El-Refaei, M., Nasif, W., El-Brairy, A. Emerging role of a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist in bronchial asthma in vivo: antioxidant activity and the down-regulation of inflammatory factors. EKB Journal Management System, 2014; 10(1): 1-13. doi: 10.21608/blj.2014.63402

Emerging role of a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist in bronchial asthma in vivo: antioxidant activity and the down-regulation of inflammatory factors

Biochemistry Letters
Article 1, Volume 10, Issue 1, 2014, Page 1-13  XML PDF (1.1 MB)
Document Type: Original Article
DOI: 10.21608/blj.2014.63402
View on SCiNiTO View on SCiNiTO
Authors
Mona M. El-Naa1; Mohamed F. El-Refaei2; Wesam A. Nasif2; Amany I. El-Brairy1
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, October University for Modern Sciences and Arts, Egypt.
2Molecular Biology Department, Genetic Engineering and Biotechnology Institute, Sadat City University, Egypt.
Abstract
 




 Objectives: To investigate the effects of a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, rosiglitazone, on induced bronchial asthma in a murine model. Material and methods: Adult male guinea pigs were administered ovalbumin 100 mg/kg S.C. and 100 mg/kg I.P. Treatment with rosiglitazone (5 mg/kg/day, PO) was assessed for 21 days. On day 21, the animals were challenged with the same dose of ovalbumin and the ratio of FEV1 (forced expiratory volume in one second) to FVC (forced vital capacity), FEV1/ FVC, was measured using a spirometer. In addition, serum levels of interleukin-5 (IL-5) and immunoglobulin E (IgE) were assessed. The activities of superoxide dismutase (SOD) and catalase and the level of reduced glutathione (GSH) were determined in lung tissue homogenates. Furthermore, histopathological examination of the lung was performed. Results: treatment with rosiglitazone resulted in a profound improvement in lung function and histopathological features. These improvements were accompanied by a significant decrease in the serum levels of IL-5 and IgE. Moreover, the activities of antioxidant enzymes, including SOD and catalase, and the GSH level were significantly increased in the lung tissues of treated animals compared to those of untreated asthmatic animals. Conclusion: PPAR-γ agonist rosiglitazone may have potential in the development of therapies for bronchial asthma. 
Statistics
Article View: 122
PDF Download: 160